Isosorbide

ANI mononitrate IR is labeled for prevention and treatment of coronary-artery-disease angina; Torrent mononitrate ER and selected Par dinitrate oral tablets for prevention of angina due to coronary disease. None of these oral products acts rapidly enough to abort an acute attack. The catalog’s unsuffixed name is interpreted within its cardiovascular classification; non-nitrate isosorbide and other nitrate routes/products are outside this scope.

The 2022 AHA/ACC/HFSA guideline recommends hydralazine plus isosorbide dinitrate for self-identified African American patients with NYHA III–IV HFrEF on optimal therapy. It may be considered for symptomatic HFrEF when ARNI/ACE inhibitor/ARB therapy cannot be used because of intolerance or renal insufficiency. This is a combination role, not approval of mononitrate or single-nitrate monotherapy for all HF. Fixed-dose BiDil and its complete titration regimen require their own reference.

Selected single-ingredient labels do not establish benefit in acute MI or acute CHF and advise against their oral formulations in those rapidly changing settings because effects are difficult to terminate. This does not negate the separate guideline HFrEF combination role. Routine continuous nitrate exposure can cause tolerance; dose escalation does not reliably reverse it.

Mononitrate IR: the two doses 7 hours apart leave a 17-hour dosing gap; some tolerance can still occur, and 24-hour protection is not promised. Dinitrate IR: preserve the prescribed ≥ 14-hour daily gap for this antianginal label regimen. Mononitrate ER: use once each morning; do not chew/crush, and swallow with half a glass of fluid. The selected 60 mg ER tablet may be halved for 30 mg; do not extrapolate splitting permission to the unscored 120 mg tablet or another manufacturer. Do not add extra doses to fill the low-exposure interval.

Mononitrate IR label says renal/hepatic or age-only adjustment is unnecessary on its PK evidence, but older-adult guidance still recommends cautious low-end selection. Mononitrate ER disposition is similar in studied renal failure/cirrhosis; no fixed eGFR reduction is provided. Dinitrate labels provide no validated fixed renal/hepatic algorithm. For every form, BP, volume depletion, interacting drugs and clinical response matter; do not infer automatic dose conversion or a dialysis replacement dose.

Follow the product-specific schedule and a clinician-directed plan for missed doses, worsening angina or headache intolerance. Selected labels give no universal missed-dose doubling rule. Do not abruptly change frequency or substitute another nitrate/release form; sustained clinical benefit depends on planned exposure and response monitoring. Use the prescribed acute chest-pain rescue/emergency plan rather than waiting for these oral tablets to act.

Current ANI mononitrate IR and Par dinitrate labels prohibit PDE5 inhibitors and riociguat, and specify nitrate/product hypersensitivity. Torrent ER section lists hypersensitivity/idiosyncrasy to nitrates/nitrites and warns about sildenafil; this narrower historical section wording does not erase the nitrate-class combination prohibition verified by the current nitrate labels. Avoid the contraindicated combinations with every nitrate form.

The selected current U.S. oral nitrate labels have no boxed warning. Severe hypotension, contraindicated interactions and form-specific dosing/tolerance restrictions remain important.

Headache and lightheadedness/dizziness are prominent; flushing, nausea and fatigue can occur. Severe hypotension, syncope, worsening angina and rare methemoglobinemia are reported; rates differ between formulations and many reports have uncertain frequency/causality. Suspected overdose needs emergency/Poison Help care (U.S. 1-800-222-1222), with supervised hemodynamic support and assessment for methemoglobinemia. Mononitrate can be dialyzed; dinitrate/metabolite dialysis utility is uncertain. These observations are not a home overdose regimen.

Never use a blanket nitrate/PDE5 washout rule across all drugs or assume changing from dinitrate to mononitrate removes risk. Review every companion medicine and the last dose time; emergency nitrate use after a PDE5 inhibitor requires clinician assessment, not self-treatment.

Mononitrate labels advise pregnancy use only if clearly needed; dinitrate requires benefit justifying fetal risk. Adequate controlled human pregnancy data are absent, and animal findings differ by dose/study. Do not turn legacy pregnancy letter categories into a safety ranking. Human milk transfer is unknown in the selected labels; use caution and discuss maternal need and potential infant exposure.

Pediatric safety/effectiveness is not established; no pediatric dose is supplied. Older-adult data are limited. Choose cautiously at the low end where appropriate and assess volume status, low BP, polypharmacy and falls; mononitrate IR’s no age-only adjustment does not mean no individual sensitivity.

Studied mononitrate disposition is not markedly changed by renal impairment/cirrhosis; IR label provides no routine adjustment and no hemodialysis replacement dose. Dinitrate undergoes extensive first-pass metabolism but has no validated organ-based fixed regimen in selected labels. Low BP, hypovolemia, HCM and unstable acute cardiac disease require separate risk assessment regardless of clearance. The HFrEF dinitrate/hydralazine role remains a distinct supervised combination.

Organic nitrates relax vascular smooth muscle, especially veins, reducing venous return and cardiac preload; arterial/coronary dilation also contributes. Mononitrate is an active dinitrate metabolite. The relative contribution of preload, afterload and coronary effects varies; the molecules/release forms still need their own regimens.

Mononitrate IR

Nearly 100% oral bioavailability, peak ~30–60 minutes and overall half-life ~5 hours; mainly inactive metabolites in urine.

Mononitrate ER

Slower formulation-dependent peak; food may slow the rate without changing overall exposure. Once-morning dosing does not imply 24-hour antianginal coverage.

Dinitrate oral

Extensive first pass; average bioavailability ~25% with wide variability, peak around 1 hour, parent half-life ~1 hour; active 5-mononitrate lasts ~5 hours.

Tolerance

Sustained continuous exposure loses effectiveness; prescribed low-exposure intervals are integral to chronic angina dosing.

Assess angina pattern, rescue use, BP/pulse, orthostatic symptoms, volume status and contraindicated/interacting medicines. Follow adherence to the correct interval, headache tolerance and loss of benefit; worsening/rest chest pain needs timely emergency assessment rather than unsupervised escalation. Review falls and organ/comorbidity changes. No routine nitrate concentration target or universal laboratory interval is established; investigate possible methemoglobinemia only when clinically indicated.

Know the full name, nitrate species and release form. Mononitrate IR uses doses 7 hours apart; selected ER uses a morning dose without crushing/chewing; dinitrate’s angina interval is different. Rise carefully and discuss alcohol. Do not use ED/PAH PDE5 medicines or riociguat with any nitrate. Discuss headache treatment, missed doses and changing therapy with the clinician. Keep the prescribed fast-acting rescue plan and seek emergency help for persistent or concerning chest pain.

Torrent isosorbide mononitrate ER 30 mg: white/off-white oval film-coated tablet with breakline and 3–0 on one side, 1104 on the other; example bottle of 100 NDC 13668-104-01. These are manufacturer-specific identifiers, not a substitute for checking the full label.

ANI IR and Torrent ER: 20–25°C; Torrent allows excursions 15–30°C. Par 5/10/20/30 mg: approximately 25°C, protect from light and keep tightly closed in tight light-resistant containers. Par 40 mg: 20–25°C, excursions 15–30°C, with the same light/tight-container protection. Keep away from children and retain release-form identification.